Información de Barinthus Biotherapeutics PLC, dividendo de Barinthus Biotherapeutics PLC, actividades de los accionistas y más

Más Datos de Barinthus Biotherapeutics PLC Compañía

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.

Información de Barinthus Biotherapeutics PLC



Símbolo de cotizaciónBRNS

Nombre de la empresaBarinthus Biotherapeutics PLC

Fecha de salida a bolsaApr 30, 2021

Director ejecutivoMr. William J. (Bill) Enright

Número de empleados105

Tipo de seguridadDepository Receipt

Fin del año fiscalApr 30

DirecciónUnit 6-10, Zeus Building, Rutherford Avenue

CiudadDIDCOT

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited Kingdom

Código postalOX11 0DF

Teléfono441865818808

Sitio Webhttps://www.barinthusbio.com/

Símbolo de cotizaciónBRNS

Fecha de salida a bolsaApr 30, 2021

Director ejecutivoMr. William J. (Bill) Enright

Ejecutivos de Barinthus Biotherapeutics PLC



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Geoffrey Lynn

Chief Scientific Officer

638.44K

--

Mr. Robin Wright

Non-Executive Independent Chairman of the Board

48.26K

--

Dr. Pierre A. Morgon, Pharm.D.

Non-Executive Independent Director

10.51K

--

Dr. Anne M. Phillips, M.D.

Non-Executive Independent Director

3.00K

--

Dr. Joseph C. Scheeren

Non-Executive Independent Director

--

Mr. William J. (Bill) Enright

Chief Executive Officer, Principal Financial Officer, Director

--

Ms. Karen T. Dawes

Non-Executive Independent Director

--

Dr. Alex Hammacher

Non-Executive Director

--

Mr. Robin Wright

Non-Executive Independent Chairman of the Board

--

Dr. Alex Hammacher

Non-Executive Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Geoffrey Lynn

Chief Scientific Officer

638.44K

--

Mr. Robin Wright

Non-Executive Independent Chairman of the Board

48.26K

--

Dr. Pierre A. Morgon, Pharm.D.

Non-Executive Independent Director

10.51K

--

Dr. Anne M. Phillips, M.D.

Non-Executive Independent Director

3.00K

--

Dr. Joseph C. Scheeren

Non-Executive Independent Director

--

Mr. William J. (Bill) Enright

Chief Executive Officer, Principal Financial Officer, Director

--

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: vie., 4 de jul

Accionistas

Tipos de accionistas

Accionistas

Proporción

Oxford Science Enterprises PLC

21.55%

M&G Investment Management Ltd.

12.73%

Cawood (Frank Wayne)

8.29%

Alphabet, Inc.

3.71%

HSG Holding Ltd.

3.48%

Otro

50.24%

Accionistas

Proporción

Oxford Science Enterprises PLC

21.55%

M&G Investment Management Ltd.

12.73%

Cawood (Frank Wayne)

8.29%

Alphabet, Inc.

3.71%

HSG Holding Ltd.

3.48%

Otro

50.24%

Tipos de accionistas

Accionistas

Proporción

Venture Capital

25.26%

Investment Advisor

17.88%

Individual Investor

13.37%

Investment Advisor/Hedge Fund

0.76%

Endowment Fund

0.30%

Corporation

0.24%

Hedge Fund

0.13%

Research Firm

0.05%

Otro

42.01%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

29

18.12M

44.37%

-542.19K

2025Q2

40

23.85M

59.01%

+716.06K

2025Q1

41

23.85M

60.03%

+745.95K

2024Q4

40

24.08M

59.87%

+1.54M

2024Q3

37

20.03M

50.21%

-349.60K

2024Q2

38

20.26M

51.12%

-213.80K

2024Q1

38

20.04M

50.62%

-468.31K

2023Q4

42

19.97M

51.73%

-616.84K

2023Q3

45

19.96M

51.78%

-695.67K

2023Q2

52

20.10M

52.29%

-1.03M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Oxford Science Enterprises PLC

8.80M

21.55%

--

Apr 14, 2025

M&G Investment Management Ltd.

5.20M

12.73%

--

Jun 30, 2025

Cawood (Frank Wayne)

3.38M

8.29%

+1.04M

+44.47%

Dec 31, 2024

Alphabet, Inc.

1.51M

3.71%

--

Jun 30, 2025

HSG Holding Ltd.

1.42M

3.48%

--

Jun 30, 2025

Enright (William)

1.24M

3.05%

--

Apr 14, 2025

DC Funds, LP

642.20K

1.57%

--

Jun 30, 2025

Lynn (Geoffrey)

638.44K

1.56%

+638.44K

--

Dec 17, 2024

Robert W. Baird & Co. Inc.

192.46K

0.47%

+100.00K

+108.15%

Jun 30, 2025

Johns Hopkins University

122.24K

0.3%

--

Jun 30, 2025

ETFs relacionados



Actualizado: hace 3 horas

Nombre

Proporción

ActivePassive International Equity ETF

0%

ActivePassive International Equity ETF

Proporción0%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos